Bupivacaine; Meloxicam Patent Expiration
Bupivacaine; Meloxicam is used for postoperative pain management in various surgical procedures. It was first introduced by Heron Therapeutics Inc
Bupivacaine; Meloxicam Patents
Given below is the list of patents protecting Bupivacaine; Meloxicam, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zynrelef Kit | US11844837 | Compositions of a polyorthoester and an organic acid excipient | Apr 21, 2036 | Heron Theraps Inc |
| Zynrelef Kit | US10098957 | Long-acting polymeric delivery systems | Apr 20, 2035 | Heron Theraps Inc |
| Zynrelef Kit | US10213510 | Long-acting polymeric delivery systems | Apr 20, 2035 | Heron Theraps Inc |
| Zynrelef Kit | US10632199 | Long-acting polymeric delivery systems | Apr 20, 2035 | Heron Theraps Inc |
| Zynrelef Kit | US10898575 | Long-acting polymeric delivery systems | Apr 20, 2035 | Heron Theraps Inc |
| Zynrelef Kit | US10980886 | Compositions of a polyorthoester and an organic acid excipient | Apr 20, 2035 | Heron Theraps Inc |
| Zynrelef Kit | US11083730 | Long-acting polymeric delivery systems | Apr 20, 2035 | Heron Theraps Inc |
| Zynrelef Kit | US11083797 | Long-acting polymeric delivery systems | Apr 20, 2035 | Heron Theraps Inc |
| Zynrelef Kit | US11413350 | Long-acting polymeric delivery systems | Apr 20, 2035 | Heron Theraps Inc |
| Zynrelef Kit | US9694079 | Long-acting polymeric delivery systems | Apr 20, 2035 | Heron Theraps Inc |
| Zynrelef Kit | US9801945 | Long-acting polymeric delivery systems | Apr 20, 2035 | Heron Theraps Inc |
| Zynrelef Kit | US10398686 | Compositions of a polyorthoester and an aprotic solvent | Mar 13, 2034 | Heron Theraps Inc |
| Zynrelef Kit | US11253504 | Compositions of a polyorthoester and an aprotic solvent | Mar 13, 2034 | Heron Theraps Inc |
| Zynrelef Kit | US9592227 | Compositions of a polyorthoester and an aprotic solvent | Mar 13, 2034 | Heron Theraps Inc |
| Zynrelef Kit | US9744163 | Compositions of a polyorthoester and an aprotic solvent | Mar 13, 2034 | Heron Theraps Inc |
| Zynrelef Kit | US9913909 | Compositions of a polyorthoester and an aprotic solvent | Mar 13, 2034 | Heron Theraps Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Bupivacaine; Meloxicam's patents.
Latest Legal Activities on Bupivacaine; Meloxicam's Patents
Given below is the list recent legal activities going on the following patents of Bupivacaine; Meloxicam.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 20 Dec, 2023 | US11844837 |
| Patent Issue Date Used in PTA Calculation Critical | 19 Dec, 2023 | US11844837 |
| Mail Patent eGrant Notification | 19 Dec, 2023 | US11844837 |
| Patent eGrant Notification | 19 Dec, 2023 | US11844837 |
| Recordation of Patent eGrant | 19 Dec, 2023 | US11844837 |
| Recordation of Patent Grant Mailed Critical | 19 Dec, 2023 | US11844837 |
| Email Notification Critical | 30 Nov, 2023 | US11844837 |
| Issue Notification Mailed Critical | 29 Nov, 2023 | US11844837 |
| Application Is Considered Ready for Issue Critical | 15 Nov, 2023 | US11844837 |
| Dispatch to FDC | 15 Nov, 2023 | US11844837 |
Bupivacaine; Meloxicam's Family Patents
